S
Silvia Gervasoni
Researcher at University of Milan
Publications - 16
Citations - 233
Silvia Gervasoni is an academic researcher from University of Milan. The author has contributed to research in topics: Virtual screening & Docking (molecular). The author has an hindex of 7, co-authored 16 publications receiving 93 citations.
Papers
More filters
Journal ArticleDOI
The VEGA suite of programs: an versatile platform for cheminformatics and drug design projects.
TL;DR: An overview of the latest release of the VEGA suite of programs, which is primarily developed for drug design studies, includes cheminformatics and modeling features, which can be fruitfully utilized in various contexts of the computational chemistry.
Journal ArticleDOI
A Comprehensive Mapping of the Druggable Cavities within the SARS-CoV-2 Therapeutically Relevant Proteins by Combining Pocket and Docking Searches as Implemented in Pockets 2.0.
Silvia Gervasoni,Giulio Vistoli,Carmine Talarico,Candida Manelfi,Andrea R. Beccari,Gabriel Studer,Gabriel Studer,Gerardo Tauriello,Gerardo Tauriello,Andrew Waterhouse,Andrew Waterhouse,Torsten Schwede,Torsten Schwede,Alessandro Pedretti +13 more
TL;DR: The presented strategy for pocket mapping based on the combination of pocket and docking searches proved successful in precisely characterizing a set of SARS-CoV-2 druggable binding pockets including both orthosteric and allosteric sites, which are clearly amenable for virtual screening campaigns and drug repurposing studies.
Journal ArticleDOI
Prenylated Curcumin Analogues as Multipotent Tools To Tackle Alzheimer's Disease.
Federica Bisceglia,Francesca Seghetti,Massimo Serra,Morena Zusso,Silvia Gervasoni,Laura Verga,Giulio Vistoli,Cristina Lanni,Michele Catanzaro,Ersilia De Lorenzi,Federica Belluti +10 more
TL;DR: The curcumin-based analogue 1 emerged as multipotent compound worthy to be further investigated and exploited in the Alzheimer's disease multitarget context.
Journal ArticleDOI
Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.
Luiz Antonio Soares Romeiro,Luiz Antonio Soares Romeiro,Jéssica Larissa da Costa Nunes,Camila de Oliveira Miranda,Gabriella Simões Heyn Roth Cardoso,Andressa Souza de Oliveira,Annachiara Gandini,Annachiara Gandini,Tereza Kobrlova,Ondrej Soukup,Michele Rossi,Johanna Senger,Manfred Jung,Silvia Gervasoni,Giulio Vistoli,Sabrina Petralla,Francesca Massenzio,Barbara Monti,Maria Laura Bolognesi +18 more
TL;DR: These first HDAC inhibitors derived from cashew nut shell liquid (CNSL), an inexpensive agro-food waste material, are developed, demonstrating that the use of inexpensive food waste materials could be successfully applied for the development of accessible and sustainable drug candidates for the treatment of AD.
Journal ArticleDOI
Combining Molecular Dynamics and Docking Simulations to Develop Targeted Protocols for Performing Optimized Virtual Screening Campaigns on The hTRPM8 Channel.
Carmine Talarico,Silvia Gervasoni,Candida Manelfi,Alessandro Pedretti,Giulio Vistoli,Andrea R. Beccari +5 more
TL;DR: The generated hTRPM8 model appears to be amenable for successful structure-based virtual screening (VS) VS studies; cross-talk modulating effects between interacting monomers on the binding sites can be accounted for by combining docking simulations as performed on all the monomers.